Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $103.9 million.

  • Axsome Therapeutics' Non-Current Assets rose 26.19% to $103.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.9 million, marking a year-over-year increase of 26.19%. This contributed to the annual value of $83.4 million for FY2024, which is 0.64% down from last year.
  • As of Q3 2025, Axsome Therapeutics' Non-Current Assets stood at $103.9 million, which was up 0.72% from $103.2 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Non-Current Assets registered a high of $103.9 million during Q3 2025, and its lowest value of $1.7 million during Q1 2022.
  • Moreover, its 3-year median value for Non-Current Assets was $85.2 million (2024), whereas its average is $90.5 million.
  • In the last 5 years, Axsome Therapeutics' Non-Current Assets spiked by 4,796.74% in 2023 and then fell by 7.58% in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Non-Current Assets stood at $85.8 million in 2022, then declined by 2.17% to $84.0 million in 2023, then dropped by 0.64% to $83.4 million in 2024, then increased by 26.19% to $103.9 million in 2025.
  • Its last three reported values are $103.9 million in Q3 2025, $103.2 million for Q2 2025, and $102.0 million during Q1 2025.